GVR Report cover Respiratory Disease Vaccine Market Size, Share & Trends Report

Respiratory Disease Vaccine Market Size, Share & Trends Analysis Report By Type (Viral Vaccine, Bacterial Vaccine, Combination Vaccine), Age Group, Distribution Channel, Infection, By Region, And Segment Forecasts, 2023 To 2030

  • Report ID: GVR454524
  • Number of Pages: 0
  • Format: Electronic (PDF)

The respiratory disease vaccine market is projected to grow at a lucrative rate over the forecast period due to rising healthcare infrastructure, growing awareness about vaccination, and growing geriatric population. Diseases that affect the lungs and other components of the respiratory system are referred to as respiratory illnesses. Some of the major causes of these diseases are asbestos, passive smoking, cigarette usage, infection, and other forms of air pollution. The best defense against chronic respiratory disorders is immunization through vaccination.

The primary factor fueling market expansion is the rising prevalence of diseases such asthma, TB, pneumonia, and lung cancer. For instance, according to the data published by American Cancer Society about in 2023, about 238,340 new lung cancer cases are projected in the U.S. and lung cancer is one of the leading cause of cancer death in the U.S. accounting for about 1 in 5 of all cancer deaths.

One of the key factors fueling the industry expansion is an increase in government support and monitoring related influenza vaccination on the national and international levels to track the supply, distribution, and administration of flu vaccines. Moreover, rising investments by key players to launch new vaccines in the market have further supported the market growth. For instance, in September 2022, Pfizer announced that they are initiating the Phae 3 rial of their mRNA based influenza vaccine. The study will include 25,000 U.S. ageing 18 and above.

The respiratory disease vaccine market is segmented based on type, infection, age group and distribution channel. Among the indication segment, COVID-19 dominated the market in 2022. Rising number of COVID cases, and increasing focus of government throughout the world in spreading awareness about COVID vaccine have boosted the segment growth. Furthermore, increasing focus of key players in launching of COVID vaccines further boosted the market growth. For instance, in January 2023, Bharat Biotech launched intranasal COVID-19 vaccine named iNCOVACC.

North America held the largest share in 2022 due presence of key players, rising healthcare infrastructure, growing cases of chronic disorders and availability of proper vaccination service. Rising number of clinical studies and growing number product launches within the region further boots the industry growth. For instance, in October 2022, GSK declared positive result for their Phase 3 trail, against RSV-lower respiratory tract disease (LRTD) for adults.

Respiratory Disease Vaccine Market Segmentation




Viral Vaccine, Bacterial Vaccine, Combination Vaccine


COVID-19, Influenza, Respiratory Syncytial Virus (RSV), Metapneumovirus, Pneumonia, Others

Age Group

Infant, Adolescent, Adult

Distribution Channel

Hospital Pharmacy, Retail Pharmacy, Others


North America, Europe, Asia Pacific, Latin America, Middle East & Africa


Key players operating in the respiratory disease vaccine market include GSK plc., Johnson & Johnson Services, Inc., Pfizer Inc., Sanofi, Serum Institute of India Pvt. Ltd., SINOVAC, Bavarian Nordic, Bayer AG, AstraZeneca, EMERGENT, Novavax, INOVIO Pharmaceuticals. Major players are investing into R&D and clinical trials of vaccine to expand their dominancy in the market. For instance, August 2022, Pfizer announced positive result of their Phase 3 Trial of older Adults for its Bivalent Respiratory Syncytial Virus (RSV) Vaccine.

gvr icn


gvr icn

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

gvr icn


We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

Contact us now to get our best pricing.

esomar icon

ESOMAR certified & member

D&B icon

Leading SME award by D&B

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.

great place to work icon